Venomyx Therapeutics on Wefunder

EpiPen for snakebites: the antivenom of tomorrow!


see other companies in category:

Venomyx Therapeutics Website

minimum raise


maximum raise


start date


stop date


security type


investment minimum


raised to date


reporting date


number of investors


percent of minimum raised


percent of maximum raised


likelihood of reaching max

Likely to Reach Max

dollars per day to reach max


dollars per day committed


dollars per day - category-


dollars per day committed - all companies

More SEC Filing Data on Venomyx Therapeutics from

Venomyx Therapeutics, with a valuation cap of $5 million, is raising crowdfunding on WeFunder. The company is developing Vipax, the world’s first broad-spectrum antivenom for snakebites. The product is ten times more effective than traditional antivenoms and much cheaper. Venomyx Therapeutics was founded by Daniel Dempsey and Deepankar Roy. The proceeds of the current crowdfunding round, with a minimum raise of $50,000, will be used to complete the preclinical trials, file an application to the FDA, and finish the research. Venomyx Therapeutics is expected to be a revolution while using biotechnology, and not animals, for the production of antivenom.